Asthma in pregnancy – from immunology to clinical management

Asma in gravidanza – dall’immunologia alla gestione clinica

Lilla T amási, Anikó Bohács, Ildikó Horváth, György Losonczy
Department of Pulmonology, Semmelweis University, Budapest, Hungary

ABSTRACT

Asthma is one of the most common chronic medical conditions that may complicate pregnancy. Asthma influences the outcome of pregnancy and, vice versa, pregnancy affects asthma severity, but the underlying immunological mechanisms of this interaction are not fully understood. As a sign of pregnancy-induced immunotolerance, attenuation of allergic responses can be detected in controlled asthmatic pregnant patients; however non controlled asthmatic pregnant women show significant asthma-associated immune reactions that may, beside other factors, influence fetal growth. Generally, although uncontrolled asthma may increase the risk of adverse perinatal outcomes, women with well-controlled and adequately treated disease during pregnancy do not develop maternal or fetal complications.

Keywords: Asthma, clinical management, immunological interactions, inflammation, pregnancy.

INTRODUCTION

Asthma is one of the most common chronic medical conditions that may complicate pregnancy, with a prevalence of 3.7 - 8.4% of all pregnancies [1]. Pregnant women with asthma represent a special challenge for asthma specialists and allergists. Asthma influences the outcome of pregnancy and, vice versa, pregnancy affects asthma severity, but the underlying immunological mechanisms of this interaction are not fully understood. Asthma represents a risk factor for several maternal and fetal complications, such as asthma exacerbations, use of steroids, hospitalizations due to asthma attacks, preeclampsia, gestational hypertension, preterm delivery, cesarean delivery, low birth weight, intrauterine growth restriction, and fetal death [2-7], posing a need for careful decision making and optimal training of physicians treating these patients. Adequate management of asthma and maintenance of optimal asthma control during pregnancy decrease perinatal risk [8,9].

The effect of asthma on pregnancy

Pregnancy is characterized by immunological tolerance (physiological immunosuppression) that blunts maternal immune response against paternal antigens expressed by the fetus [10]. Physiological pregnancy has been described as a Th2-dominated state, and current studies show that proliferating regulatory T cells (Tregs) may have a key role in the maintenance of peripheral tolerance to paternal antigens during pregnancy [11]. Treg cells, however, exert an inhibitory effect on natural killer lymphocytes responsible for protection against viruses [12] that may contribute to increased susceptibility to viral...
infections (e.g. influenza), as observed with H1N1 influenza in pregnant women [13]. Diminished numbers of Treg cells in pregnancy were associated with immunological rejection of the fetus as well as preeclampsia and low fetal birth weight [14]. Asthma is traditionally considered as an allergic T helper cell 2 (Th2) type inflammation that leads to bronchial hyperresponsiveness, airway obstruction and – in some cases – tissue remodeling [15]. Immunological changes in asthmatic pregnancy are not well established. In a recent study we found signs of pregnancy-induced attenuation of allergic responses. Activated pools within CD4 and CD8 T cells were larger, and the number of natural killer T (NKT) cells was increased both in non-pregnant asthmatic and in healthy pregnant subjects (compared to non-pregnant healthy controls), but in (mostly well controlled) pregnant asthmatics no further lymphocyte activation was observed suggesting that the immunosuppressive effect of uncomplicated pregnancy may blunt the lymphocyte activation which characterizes asthma [16]. On the other hand, in our earlier study a significant amount of interferon (IFN)-γ producing cells was detected in peripheral blood obtained from not well controlled asthmatic pregnant women and a significant negative correlation was revealed between the number of IFN-γ positive T-cells and birth weight of newborns, pointing at fetal growth retardation related to active, asthma-associated maternal immune reactions [17]. In addition, considering another inflammatory marker, heat shock protein (Hsp)-70, higher circulating levels were detected in pregnant asthmatic women than in healthy pregnant women. Fetal birth weight is lower in pregnancies complicated with asthma, showing a relationship between asthmatic immune responses and altered fetal growth [18]. Supporting the possible adverse effect of asthmatic inflammation on pregnancy, in a recent database cohort of 13,100 pregnant asthmatics, a 33% increased risk of perinatal mortality was observed in the pregnancies of women with asthma [4]. Major factors contributing to this increased perinatal mortality might be maternal obesity and smoking, as well as uncontrolled asthma [5]. Another recent study of pregnant women with physician-diagnosed asthma evaluated their asthma control repeatedly during pregnancy based on symptom frequency and interference with daily activities and sleep, and reported hospitalizations and unscheduled clinic visits for asthma exacerbations. According to their results, the incidence of preterm delivery is higher among patients with inadequate asthma symptom control during the first part of pregnancy compared to patients with adequate asthma control, and patients who are hospitalized for asthma during pregnancy have a higher incidence of preterm delivery compared to asthmatic women without a history of hospitalization. Thus there may be a risk for preterm delivery posed by poorly controlled maternal asthma [8]. Maternal asthma is also known as a risk factor for the development of asthma in children [19].

Influence of pregnancy on the course of asthma

Pregnancy has also an effect on the course of asthma. Asthma improves during pregnancy in about one-third, remains the same in another one-third, and worsens in one-third of pregnant women. More severe asthma before pregnancy represents a higher risk of worsening during pregnancy and there is a concordance between the courses of asthma during subsequent pregnancies [20]. Asthma-specific quality of life in early pregnancy is related to subsequent asthma morbidity during pregnancy [21]. Severity of asthma symptoms during pregnancy may also be influenced by fetal gender. Worsened asthma symptoms [22] and higher incidence of intrauterine growth retardation [23] were observed in pregnant asthmatics with female fetuses. On the other hand, obesity was also associated with an increased risk of asthma exacerbations during pregnancy [3]. In addition, maternal obesity without asthma influences also pregnancy negatively by increasing the risk for adverse perinatal outcomes (preeclampsia, gestational diabetes, intrauterine fetal retardation and fetal death) [24]. However, immunological mechanisms underlying alteration of the course of asthma during pregnancy or predicting biomarkers of worsening are largely unknown.

Management of asthma during pregnancy

Diagnosis and monitoring

Due to the bilateral interactions of asthma and pregnancy and alterations of asthma severity during pregnancy, establishing optimal asthma management during gestation often represents a special challenge for the attending physician. The diagnosis of asthma is usually known already before pregnancy. However, if first symptoms occur during gestation, reduced forced expiratory volume in one second (FEV1) or ratio of FEV1 to forced vital capacity (FVC), together with a 12% or greater improvement in FEV1 after inhalation of rapid acting beta-agonist, confirm the diagnosis of asthma. Testing bronchial hyperresponsiveness is contraindicated during pregnancy (because of the lack of safety data); thus women with a clinical picture of new-onset asthma without spirometric confirmation of the diagnosis should be treated for asthma during pregnancy [25]. Skin prick tests are not recommended during pregnancy (risk of systemic reactions); but specific IgE antibodies to suspected allergens may be evaluated [25]. Assessment of asthma control level in pregnant asthmatics is similar to the method applied in non-pregnant patients [7]. Fractioned concentration of nitric oxide present in exhaled breath (FeNO) has been evaluated as a simple and non-invasive tool for assessing airway inflammation in asthma [26]. Our recent study provided data supporting high reproducibility of FeNO measurement in pregnant subjects. According to the results pregnancy itself does not alter FeNO levels either in healthy or in asthmatic patients and FeNO levels of pregnant asthmatic patients correlate with the level of asthma control [27]. A single-blind trial of corti-
corticosteroid therapy based on either FeNO measurements or current guidelines showed lower daily dose of inhaled corticosteroid in the FeNO group [28]. Since reaching asthma control by using the lowest possible required dose is critical in pregnant asthmatics, exhaled NO measurement may have importance in this patient group.

**Treatment**

Asthmatic pregnant patients should be educated about their disease and its treatment (Table I), as strongly recommended in the GINA guidelines [7]. Smoking cessation is necessary for asthmatic pregnant women, due to known adverse effects of smoking on mother’s disease as well as the known higher risk for neonatal asthma in asthmatic pregnant women who smoke [29]. According to data on adverse effects of asthma medications in pregnancy, most of the findings are reassuring [25]. Many observational studies have shown no increased perinatal risks associated with the use of currently available inhaled beta-agonists and corticosteroids [30-33]. The use of bronchodilators during pregnancy was associated with an increased risk of gastrochisis among infants in one study [34]. Higher risk of cardiac defects was also observed in newborns of asthmatic pregnant women in one study [35]; however, asthma exacerbation itself during pregnancy may increase the risk of congenital malformations [36].

Generally, according to currently available safety data albuterol is the reliever medication of preference. Considering inhaled corticosteroids, budesonide is the preferred choice due to reassuring data in human pregnancies [32]. Among the long-acting inhaled beta-agonists, formoterol and salmeterol may be used as add-on therapy in pregnant patients if warranted by symptoms occurring despite regularly used inhaled corticosteroid therapy. Leukotriene-receptor antagonists montelukast and zafirlukast seemed also to be safe during gestation, but the available human data are scarce [9]. In one recent study enrolling 180 asthmatic pregnant women taking montelukast, no increase in the rate of major congenital malformations was observed [37]. Pregnant patients with well-controlled asthma should continue taking their medications. Although in non pregnant and permanently well-controlled asthmatics the guidelines recommend consideration of a step down in therapy [7], in pregnant well-controlled patients the maintenance of controller treatment may be decided in order to reduce the risk of control loss. Therapy should be increased by one step in patients with asthma that is not well controlled (Table II). A two-step increase, a course of oral corticosteroids, or both should be recommended for women with asthma that is very poorly controlled (Table II) [25].

Monthly asthma control assessment is recommended for women who require controller therapy during pregnancy. Optimal obstetrical care of not well controlled asthmatic pregnant patients means more frequent ultrasonographic examinations (to monitor fetal growth, which can be affected by uncontrolled asthma) and assessment of fetal well-being (nonstress

| TABLE I: MAIN PATIENT EDUCATIONAL TOPICS FOR ASTHMATIC PREGNANT PATIENTS |
|-------------------------------|--------------------------------------------------|
| Main patient educational topics | Description                                      |
| General information           | Basic information about asthma and its relationship to pregnancy Facts regarding mother and fetus safety |
| Use of inhaler devices        | Demonstration of correct use of devices prescribed to the patient |
| Adherence to treatment        | Necessity of regular visits and proper controller medication during pregnancy complicated with asthma |
| Environmental control measures to reduce exposure to allergens and irritants | Avoidance of known allergens and smoking |
| Self-Treatment action plan    | Written schedule for maintenance therapy and doses of rescue medication for increased symptoms; education about signs of asthma exacerbation and urgent or emergency help providers |

| TABLE II: STEPS OF ASTHMA MAINTENANCE THERAPY DURING PREGNANCY |
|----------------------|--------------------------------------------------|
| Step | Preferred controller medication | Alternative controller medication |
| 1    | none | - |
| 2    | Low-dose inhaled corticosteroid | LTRA, cromolyn, theophylline |
| 3    | Medium-dose inhaled corticosteroid | Low-dose inhaled corticosteroid + LABA or LTRA or theophylline |
| 4    | Medium-dose inhaled corticosteroid + LABA | Low-dose inhaled corticosteroid + LTRA or theophylline |
| 5    | High-dose inhaled corticosteroid + LABA | - |
| 6    | High-dose inhaled corticosteroid + LABA + oral corticosteroid | - |

**Definition of abbreviations:** LTRA, leukotriene-receptor antagonist; LABA, long-acting beta-agonist.

From [25] with permission.
testing from the 32nd gestational week). During labor and delivery the use of asthma medications should be continued. Women who have received systemic corticosteroids during pregnancy are recommended to receive intravenous corticosteroids during labor and for 24 hours after delivery [25].

In conclusion, asthma is probably one of the most common chronic diseases complicating pregnancy and influencing its outcome. Generally, although uncontrolled asthma may increase the risk of adverse perinatal outcomes, women with well-controlled, adequately treated disease during pregnancy do not develop maternal or fetal complications. Good and frequent communication between obstetrics, pulmonologists, allergist and general practitioners is a vital necessity of asthma treatment during pregnancy.

ACKNOWLEDGEMENT: This study was supported by the Hungarian Scientific Research Foundation (OTKA K- 68758). The authors thank Professor Michael Schatz from Kaiser-Permanente Medical Center, San Diego, CA for his kind permission to use data of Table II.

CONFLICT OF INTEREST STATEMENT: None of the authors has any conflict of interest to declare in relation to the subject matter of this manuscript.

References

1. Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. Ann Epidemiol 2003;13:317-324.

2. Demissie K, Bredenridge MB, Rhoads GG. Infant and maternal outcomes in the pregnancies of asthmatic women. Am J Respir Crit Care Med 1998;158:1091-1095.

3. Hendler I, Schatz M, Momirnova V, Wise R, Landon M, Mabie W, Newman RB, Kiley J, Hauth JC, Moawad A, Caritis SN, Spong CY, Leveno KJ, Miodovnik M, Meis P, Wapner RJ, Paul RH, Varner MW, O’Sullivan MJ, Thornau GR, Conway DL; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Association of obesity with pulmonary and non-pulmonary complications of pregnancy in asthmatic women. Obstet Gynecol 2006;108:77-82.

4. Breton MC, Beauchesne MF, Lemière C, Rey E, Forget A, Blais L. Risk of perinatal mortality associated with asthma during pregnancy. Thorax 2009;64:101-106.

5. Schatz M. Is maternal asthma a life or death issue for the baby? Thorax 2009;64:93-95.

6. Schatz M, Dombrowski MP, Wise R, Momirova V, Landon M, Mabie W, Newmark RB, Rouse DJ, Lindheimer M, Miodovnik M, Caritis SN, Leveno KJ, Meis P, Wapner RJ, Paul RH, O’Sullivan MJ, Varner MW, Thornau GR, Conway DL; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Association of obesity with pulmonary and non-pulmonary complications of pregnancy in asthmatic women. Obstet Gynecol 2006;108:77-82.

7. GINA Report. Global Strategy for Asthma Management and Prevention 2007 (update). www.ginaasthma.org.

8. Bakhireva LN, Schatz M, Jones KL, Chambers CD; Organization of Teratology Information Specialists Collaborative Research Group. Asthma control during pregnancy and the risk of preterm delivery or impaired fetal growth. Ann Allergy Asthma Immunol 2008;101:137-143.

9. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the Diagnosis and Management of Asthma. Full report 2007. (Accessed February 3, 2010, at http://www.nhlbi.nih.gov/guidelines/asthma/astghdlp.pdf.).

10. Saito S, Shiozaki A, Sasaki Y, Nakashima A, Shima T, Ito M. Regulatory T cells and regulatory natural killer (NK) cells play important roles in fetot-maternal tolerance. Semin Immunopathol 2007;29:115-122.

11. Somers et DA, Zheng Y, Killiy MD, Sansom DM, Dooyson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 2004;112:38-43.

12. Trzonkowski P, Szmit E, Myśliwska J, Dobyszuk A, Myśliwska A. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004;112:258-267.

13. Su LL, Chan J, Chong YS, Choulan M, Biswas A, Yong EL. Pregnancy and H1N1 infection. Lancet 2009;374:1417.

14. Toldi G, Svec P, Vásárhelyi B, Mészáros G, Rigó J, Túlassy T, Treszl A. Decreased number of FoxP3+ regulatory T cells in preeclampsia. Acta Obstet Gynecol Scand 2008;87:1229-1233.

15. Lloyd CM, Hawrylyszcz CM. Regulatory T cells in asthma. Immunity 2009;31:438-449.

16. Bohács A, Pällinger E, Tamási L, Rigó J Jr, Komlósi Z, Müller V, Dong Y, Magyar P, Falus A, Losonczy G. Surface markers of lymphocyte activation in pregnant asthmatics. Inflamm Res 2010;59:64-70.

17. Tamási L, Bohács A, Pällinger E, Falus A, Rigó J Jr, Müller V, Komlósi Z, Magyar P, Losonczy G. Increased interleukin-gamma- and interleukin-4-synthesizing subsets of circulating lymphocytes in pregnant asthmatics. Clin Exp Allergy 2005;35:1197-1203.

18. Tamási L, Bohács A, Tamási V, Stenczer B, Prohászka Z, Rigó J Jr, Losonczy G, Molvarec A. Increased circulating heat shock protein 70 levels in pregnant asthmatics. Cell Stress Chaperones 2010;15:295-300.

19. Latzin P, Frey U, Rošia HL, Baldwin DN, Regamey N, Strippoli MP, Zwahlen M, Kuehni CE; Swiss Paediatric Respiratory Research Group. Prospectively assessed incidence, severity, and determinants of respiratory symptoms in the first year of life. Pediatr Pulmonol 2007;42:41-50.

20. Schatz M. Interrelationships between asthma and pregnancy: a literature review. J Allergy Clin Immunol 1999;103:S310-S316.

21. Schatz M, Dombrowski MP, Wise R, Lai Y, Landon M, Newman RB, Rouse DJ, Miodovnik M, O’Sullivan MJ, Caritis SN, Leveno KJ, Wapner RJ, Conway DL; Eunice Kennedy Shriver National Institute Of Child Health And Human Development Maternal-Fetal Medicine Units Network. Association of obesity with pulmonary and non-pulmonary complications of pregnancy in asthmatic women. Obstet Gynecol 2006;108:77-82.

22. Schatz M. Interrelationships between asthma and pregnancy: a literature review. J Allergy Clin Immunol 1999;103:S310-S316.

23. Schatz M, Dombrowski MP, Wise R, Lai Y, Landon M, Newman RB, Rouse DJ, Miodovnik M, O’Sullivan MJ, Caritis SN, Leveno KJ, Wapner RJ, Conway DL; Eunice Kennedy Shriver National Institute Of Child Health And Human Development Maternal-Fetal Medicine Units Network And The National Heart Lung And Blood Institute. The relationship of asthma-specific quality of life during pregnancy to subsequent asthma and perinatal morbidity. J Asthma 2010;47:46-50.

24. Bakhireva LN, Schatz M, Jones KL, Tucker CM, Slymen DJ, Klônöfl-Cohen HS, Gresham L, Johnson D, Chambers CD; OTIS Collaborative Research Group. Fetal sex and maternal asthma control in pregnancy. J Asthma 2008;45:403-407.

25. Murphy VE, Gibson PG, Giles WB, Zaker T, Smith R, Bisits AM, Kessell CG, Clifton VL. Maternal asthma is associated with reduced female fetal growth. Am J Respir Crit Care Med 2003;168:1317-1323.
24. Cedergren MI. Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstet Gynecol 2004;103:219-224.

25. Schatz M, Dombrowski MP. Clinical practice. Asthma in pregnancy. N Engl J Med 2009;360:1862-1869.

26. Horváth I, Donnelly LE, Kiss A, Kharitonov SA, Lim S, Chung KF, Barnes PJ. Combined use of exhaled hydrogen peroxide and nitric oxide in monitoring asthma. Am J Respir Crit Care Med 1998;158:1042-1046.

27. Tamási L, Bohács A, Bikov A, Andorka C, Rigó Jr, Losonczy G, Horváth I. Exhaled nitric oxide in pregnant healthy and asthmatic women. J Asthma 2009;46:786-791.

28. Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007;176:231-237.

29. Davidson R, Roberts SE, Wotton CJ, Goldacre MJ. Influence of maternal and perinatal factors on subsequent hospitalisation for asthma in children: evidence from the Oxford record linkage study. BMC Pulm Med 2010;10:14.

30. Schatz M, Dombrowski MP, Wise R, Morimoto V, Landon M, Mahie W, Newman RB, Hauth JC, Lindheimer M, Caritis SN, Leveno KJ, Meiss P, Moskowitz M, Waggoner RJ, Paul RH, Varney MW, O’Sullivan MJ, Thurnau GR, Conway DL; Maternal-Fetal Medicine Units Network, The National Institute of Child Health and Development; National Heart, Lung and Blood Institute. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol 2004;113:1040-1045.

31. Bakhireva LN, Jones KL, Schatz M, Johnson D, Chambers CD; Organization Of Teratology Information Services Research Group. Asthma medication use in pregnancy and fetal growth. J Allergy Clin Immunol 2005;116:503-509.

32. Källén B, Rydholm H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999;93:392-395.

33. Tamás L, Sornoski A, Müller V, Báráfiz Z, Acs N, Puhó E, Czeizel AE. A population-based case-control study on the effect of bronchial asthma during pregnancy for congenital abnormalities of the offspring. J Asthma 2006;43:81-86.

34. Lin S, Munsie JP, Herdt-Losavio ML, Bell E, Druschel C, Romitti PA, Olney R; National Birth Defects Prevention Study. Maternal asthma medication use and the risk of gastroschisis. Am J Epidemiol 2008;168:73-79.

35. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants. Eur J Clin Pharmacol 2007;63:383-388.

36. Blais L, Forget A. Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women. J Allergy Clin Immunol 2008;121:1379-1384.

37. Sarkar M, Koren G, Kalra S, Ying A, Smorlesi C, De Santis M, Diav-Citrin O, Avgil M, Voyer Lavigne S, Berkovich M, Einanson A. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol 2009;65:1259-1264.